Table 1.

Baseline characteristics.

Baseline Characteristics	Main cohort (n = 30)	Expanded access arm (n = 5)
	% (n)/Mean (SD)	% (n)/Mean (SD)
Age at Screening (years)	57.1 (10.3)	53.8 (13.9)
Family History of ALS	10.0% (3)	0.0% (0)
Male	53.3% (16)	80.0% (4)
Caucasian	93.3% (28)	100.0% (5)
Symptom onset to Diagnosis (in months)	13.2 (12.6)	8.9 (6.4)
Symptom onset to Screening (in months)	24.4 (15.7)	22.8 (9.0)
Limb Onset	66.7% (20)	60.0% (3)
Baseline SVC (% predicted)	77.0 (23.2)	81.0 (17.6)
ALSFRS-R at Baseline	37.2 (4.7)	31.6 (11.6)
Estimated ALSFRS-R Slope Pre-Baseline (48-Baseline ALSFRS-R/disease duration) (points/month)	0.58 (0.37)	0.70 (0.33)
UMNB Total at Screening	29.4 (3.5)	27.0 (10.5)
Exposure to 30-day stable dose of Riluzole	83% (25)	100% (5)
Exposure to edaravone	37% (11)	20% (1)